Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | RAF1 | P04049 | 8/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487547 | 0.78 | MAPK14 (0.56) | MAPK14RAF1YEATS4MAPK13MAPK12 | |
| SCHEMBL13315099 | 0.69 | YEATS4 (0.50) | MAPK14YEATS4LMNA | |
| SCHEMBL3197114 | 0.65 | CCNE1 (0.41) | — | |
| SCHEMBL3552734 | 0.65 | MAPK14 (1.00) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL13456099 | 0.65 | MAPK14 (0.57) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL3551747 | 0.64 | MAPK14 (0.55) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL668558 | 0.63 | RAF1 (0.49) | MAPK14RAF1RXFP1MAPK13MAPK12 | |
| SCHEMBL10264610 | 0.63 | RAF1 (0.48) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL6197998 | 0.63 | LMNA (0.49) | LMNA | |
| SCHEMBL3244736 | 0.63 | RAF1 (0.64) | MAPK14RAF1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885RAF1 74/4885RXFP1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.